DK0799618T3 - Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer - Google Patents

Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer

Info

Publication number
DK0799618T3
DK0799618T3 DK97301984T DK97301984T DK0799618T3 DK 0799618 T3 DK0799618 T3 DK 0799618T3 DK 97301984 T DK97301984 T DK 97301984T DK 97301984 T DK97301984 T DK 97301984T DK 0799618 T3 DK0799618 T3 DK 0799618T3
Authority
DK
Denmark
Prior art keywords
cancer
drug
alpha1
prevention
manufacture
Prior art date
Application number
DK97301984T
Other languages
Danish (da)
English (en)
Inventor
Timothy C Thompson
Michael G Wyllie
Guang Yang
Original Assignee
Pfizer
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Baylor College Medicine filed Critical Pfizer
Application granted granted Critical
Publication of DK0799618T3 publication Critical patent/DK0799618T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK97301984T 1996-03-27 1997-03-24 Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer DK0799618T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1422896P 1996-03-27 1996-03-27

Publications (1)

Publication Number Publication Date
DK0799618T3 true DK0799618T3 (da) 2005-05-30

Family

ID=21764236

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97301984T DK0799618T3 (da) 1996-03-27 1997-03-24 Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer

Country Status (16)

Country Link
US (1) US5935962A (fr)
EP (1) EP0799618B1 (fr)
JP (1) JPH10101579A (fr)
KR (1) KR970064607A (fr)
AT (1) ATE294582T1 (fr)
AU (1) AU733146B2 (fr)
CA (1) CA2201089A1 (fr)
DE (1) DE69733169T2 (fr)
DK (1) DK0799618T3 (fr)
ES (1) ES2242207T3 (fr)
HU (1) HUP9700661A3 (fr)
IL (2) IL120303A0 (fr)
MY (1) MY126321A (fr)
NZ (1) NZ314488A (fr)
TW (1) TW504386B (fr)
ZA (1) ZA972601B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1145482B1 (fr) * 1999-01-27 2019-01-02 Callahan Cellular L.L.C. Procédé destiné à prouver l'authenticité d'une entité ou l'intégrité d'un message au moyen d'un exposant public égal à une puissance de deux
WO2002015895A2 (fr) * 2000-08-24 2002-02-28 The Regents Of The University Of California Alpha-difluoromethylornithine (dfmo) utile pour supprimer les taux de polyamine prostatique chez l'homme
PT1293198E (pt) * 2001-09-14 2005-06-30 Kissei Pharmaceutical Co Lda Dispositivo de administracao transdermica para o tratamento de patologias do tracto urinario
US8222253B2 (en) * 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
WO2007109142A2 (fr) * 2006-03-17 2007-09-27 Oregon Health & Science University Antagonistes du recepteur muscarinique m3 pour le traitement des tumeurs exprimant le recepteur muscarinique m3
WO2009131196A1 (fr) * 2008-04-24 2009-10-29 武田薬品工業株式会社 Dérivé de pyrrolidine substituée et ses utilisations
CA2811061A1 (fr) 2010-06-30 2012-01-05 Galderma Research & Development Methode de prevention ou de traitement de tumeur de la peau
WO2012001064A2 (fr) * 2010-06-30 2012-01-05 Galderma Research & Development Procédé de prévention ou de traitement des tumeurs cutanées
US20120178757A1 (en) * 2010-12-09 2012-07-12 Nottingham University Hospitals Nhs Trust Method For The Prevention Of Cancer Metastasis
GR20200100456A (el) * 2020-08-03 2022-03-09 Inderes Ltd, Συνδυασμος φαρμακων και χρηση του στη θεραπεια του καρκινου

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent
DK0564093T3 (da) * 1992-04-01 2000-03-27 Pfizer Hydroxylerede metabolitter og derivater af doxazosin som antiatherosklerosemidler
FR2694495B1 (fr) * 1992-08-05 1994-09-23 Synthelabo Préparation pharmaceutique transdermique contenant de l'alfuzosine.
US5578611A (en) * 1992-11-13 1996-11-26 Synaptic Pharmaceutical Corporation Use of α-1C specific compounds to treat benign prostatic hyperplasia
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents

Also Published As

Publication number Publication date
CA2201089A1 (fr) 1997-09-27
ES2242207T3 (es) 2005-11-01
EP0799618B1 (fr) 2005-05-04
JPH10101579A (ja) 1998-04-21
ATE294582T1 (de) 2005-05-15
HUP9700661A3 (en) 1999-06-28
NZ314488A (en) 2000-09-29
HUP9700661A2 (hu) 1998-11-30
IL120495A0 (en) 1997-07-13
IL120303A0 (en) 1997-06-10
DE69733169T2 (de) 2006-01-19
IL120495A (en) 2004-09-27
DE69733169D1 (de) 2005-06-09
MY126321A (en) 2006-09-29
EP0799618A3 (fr) 1997-11-12
KR970064607A (ko) 1997-10-13
US5935962A (en) 1999-08-10
ZA972601B (en) 1998-09-28
EP0799618A2 (fr) 1997-10-08
HU9700661D0 (en) 1997-05-28
TW504386B (en) 2002-10-01
AU1656997A (en) 1997-10-02
AU733146B2 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
DE60010456D1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
IS4972A (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
ATE301994T1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda- antagonist
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
DK0998287T3 (da) Anvendelse af levobupivacain
ATE333896T1 (de) Vaskularisierungsinhibitoren
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
SE9603725D0 (sv) New teatment
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ZA972601B (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
BR0307022A (pt) Método de tratamento de um paciente que precisa de analgesia
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DE69733557D1 (de) Endothelin-antagonisten zur behandlung von herzversagen
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
DE60004833D1 (de) Paracetamol und buspiron enthaltende pharmazeutische zusammensetzung mit analgetischer wirkung
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
DK0711163T3 (da) Anvendelse af benzydamin i behandlingen af patologiske tilstande forårsaget af TNF
DK1037637T3 (da) Anvendelse af 5HT1A-receptor-antagonister til forebyggelse og/eller behandling af temporallapepilepsi
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
DK1019066T3 (da) Fremgangsmåder og præparater til forebyggelse og behandling af halsbrand
EE04951B1 (et) R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks